{
    "nctId": "NCT00902668",
    "briefTitle": "Lovastatin in Reducing Side Effects After Radiation Therapy in Women With Breast Cancer",
    "officialTitle": "A Phase II Study Using Lovastatin to Improve Cosmetic Outcome After Radiation Therapy for Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Radiation Toxicity",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 3,
    "primaryOutcomeMeasure": "Proportion of Good/Excellent Cosmetic Outcome During the First 5 Years After Radiotherapy",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of invasive or in situ epithelial cancer of the breast\n\n  * Stage 0, I, or II (Tis, T1, or T2) disease\n  * Unifocal disease (single focus that can be encompassed by breast-conserving surgery)\n* Has undergone prior surgical resection of the primary lesion (lumpectomy) and axillary nodal evaluation (if invasive disease is present)\n\n  * Negative surgical margins (\u2265 1 mm)\n* Planning to undergo radiotherapy with either standard external beam radiotherapy or accelerated partial breast irradiation (interstitial or balloon brachytherapy)\n* No Paget disease of the nipple\n* No evidence of distant metastases\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* Karnofsky performance status 70-100%\n* Transaminases \\< 3 times upper limit of normal (ULN)\n* Creatine kinase \\< 5 times ULN\n* Creatinine clearance \u2265 30 mL/min\n* Negative pregnancy test\n* No active liver or muscle disease\n* No history of collagen vascular disease (e.g., systemic lupus erythematosus, scleroderma, or dermatomyositis)\n* History of prior malignancy allowed provided life expectancy is \u2265 4 years\n* No major medical or psychiatric illness that, in the investigator's opinion, would prevent completion of study treatment or interfere with follow-up\n* No contraindication to an HMG-coA-reductase inhibitor\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior radiotherapy to the breast, lung, or mediastinum\n\n  * Prior radiotherapy to the contralateral breast allowed\n* No chemotherapy for \u2265 2 weeks prior to, during, and for \u2265 2 weeks after completion of radiotherapy\n* No concurrent cytochrome P450 3A4 inhibitors\n* Concurrent HMG-coA-reductase inhibitor allowed provided patient is able to switch to 20 mg of lovastatin per day\n* Concurrent tamoxifen or an aromatase inhibitor allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}